Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-Week Open-Label Extension Study of Pimavanserin in Major Depressive Disorder
2018-003252-20Phase 3Unknown
- Sponsor
- Acadia Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in major depressive disorder (MDD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events (TEAEs). Status: unknown.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-003252-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003252-20.